File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of acute cerebral hemorrhage with intravenous glycerol: A double-blind, placebo-controlled, randomized trial

TitleTreatment of acute cerebral hemorrhage with intravenous glycerol: A double-blind, placebo-controlled, randomized trial
Authors
Issue Date1992
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://stroke.ahajournals.org
Citation
Stroke, 1992, v. 23 n. 7, p. 967-971 How to Cite?
AbstractBackground and Purpose: Hitherto, treatment of acute cerebral hemorrhage with intravenous glycerol has not been evaluated in rigorous clinical studies with sufficient patient numbers. Methods: We undertook a double-blind, stratified and randomized, placebo-controlled clinical trial. Only patients with a first stroke admitted to the hospital within 24 hours after onset of symptoms were recruited, provided computed tomography confirmed hemorrhage and informed consent was obtained. After stratification into alert, semicoma, and coma subgroups using the Glasgow Coma Scale, 107 patients received active treatment (500 ml of 10% glycerol in saline by intravenous infusion over 4 hours on 6 consecutive days) and 109 were given corresponding saline treatment. Using a variety of objective scoring systems, patients were followed up for up to 6 months. Results: At follow-up, all measures of outcome in the treated and control groups were very similar. At 6 months, respective mortality rates were 37 of 107 and 33 of 109. Corresponding mean±SD improvements in Scandinavian Stroke Study Group scores were 8.35±16.9 versus 11.55±15.6 (long-term) and 0.64±7.3 versus 2.40±6.9 (prognostic), and improvements in the Barthel Index ratings were 10.72±24.7 versus 13.95±23.3, respectively. Glasgow Coma Scale score improvements in the survivors were 0.81±1.5 and 1.16±1.7 in the treated and control groups, respectively. Hemolysis (generally subclinical) was the only adverse effect of glycerol noted. Conclusions: In the absence of any clinically or statistically significant difference in outcome between the treated and control groups, this trial provides no justification for glycerol therapy following acute cerebral hemorrhage.
Persistent Identifierhttp://hdl.handle.net/10722/161936
ISSN
2015 Impact Factor: 5.787
2015 SCImago Journal Rankings: 3.671
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYu, YLen_US
dc.contributor.authorKumana, CRen_US
dc.contributor.authorLauder, IJen_US
dc.contributor.authorCheung, YKen_US
dc.contributor.authorChan, FLen_US
dc.contributor.authorKou, Men_US
dc.contributor.authorChang, CMen_US
dc.contributor.authorCheung, RTFen_US
dc.contributor.authorFong, KYen_US
dc.date.accessioned2012-09-05T05:16:09Z-
dc.date.available2012-09-05T05:16:09Z-
dc.date.issued1992en_US
dc.identifier.citationStroke, 1992, v. 23 n. 7, p. 967-971en_US
dc.identifier.issn0039-2499en_US
dc.identifier.urihttp://hdl.handle.net/10722/161936-
dc.description.abstractBackground and Purpose: Hitherto, treatment of acute cerebral hemorrhage with intravenous glycerol has not been evaluated in rigorous clinical studies with sufficient patient numbers. Methods: We undertook a double-blind, stratified and randomized, placebo-controlled clinical trial. Only patients with a first stroke admitted to the hospital within 24 hours after onset of symptoms were recruited, provided computed tomography confirmed hemorrhage and informed consent was obtained. After stratification into alert, semicoma, and coma subgroups using the Glasgow Coma Scale, 107 patients received active treatment (500 ml of 10% glycerol in saline by intravenous infusion over 4 hours on 6 consecutive days) and 109 were given corresponding saline treatment. Using a variety of objective scoring systems, patients were followed up for up to 6 months. Results: At follow-up, all measures of outcome in the treated and control groups were very similar. At 6 months, respective mortality rates were 37 of 107 and 33 of 109. Corresponding mean±SD improvements in Scandinavian Stroke Study Group scores were 8.35±16.9 versus 11.55±15.6 (long-term) and 0.64±7.3 versus 2.40±6.9 (prognostic), and improvements in the Barthel Index ratings were 10.72±24.7 versus 13.95±23.3, respectively. Glasgow Coma Scale score improvements in the survivors were 0.81±1.5 and 1.16±1.7 in the treated and control groups, respectively. Hemolysis (generally subclinical) was the only adverse effect of glycerol noted. Conclusions: In the absence of any clinically or statistically significant difference in outcome between the treated and control groups, this trial provides no justification for glycerol therapy following acute cerebral hemorrhage.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://stroke.ahajournals.orgen_US
dc.relation.ispartofStrokeen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshCerebral Hemorrhage - Drug Therapyen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshGlycerol - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshHemoglobinuria - Chemically Induceden_US
dc.subject.meshHemolysisen_US
dc.subject.meshHumansen_US
dc.subject.meshInjections, Intravenousen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPlacebosen_US
dc.titleTreatment of acute cerebral hemorrhage with intravenous glycerol: A double-blind, placebo-controlled, randomized trialen_US
dc.typeArticleen_US
dc.identifier.emailCheung, RTF:rtcheung@hku.hken_US
dc.identifier.authorityCheung, RTF=rp00434en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1161/01.STR.23.7.967-
dc.identifier.pmid1615546-
dc.identifier.scopuseid_2-s2.0-0026632834en_US
dc.identifier.volume23en_US
dc.identifier.issue7en_US
dc.identifier.spage967en_US
dc.identifier.epage971en_US
dc.identifier.isiWOS:A1992JB59100007-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridYu, YL=8094845300en_US
dc.identifier.scopusauthoridKumana, CR=7005112381en_US
dc.identifier.scopusauthoridLauder, IJ=35564928000en_US
dc.identifier.scopusauthoridCheung, YK=7202111404en_US
dc.identifier.scopusauthoridChan, FL=7202586444en_US
dc.identifier.scopusauthoridKou, M=7004545950en_US
dc.identifier.scopusauthoridChang, CM=7407031960en_US
dc.identifier.scopusauthoridCheung, RTF=7202397498en_US
dc.identifier.scopusauthoridFong, KY=8913866800en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats